Published in J Clin Oncol on May 01, 1999
Axillary recurrence rate in breast cancer patients with negative sentinel lymph node (SLN) or SLN micrometastases: prospective analysis of 150 patients after SLN biopsy. Ann Surg (2005) 1.14
Outcomes and quality of life following breast cancer treatment in older women: when, why, how much, and what do women want? Health Qual Life Outcomes (2003) 1.08
Lymph node ratio is more valuable than level III involvement for prediction of outcome in node-positive breast carcinoma patients. World J Surg (2007) 1.00
Reassessing the role of axillary lymph-node dissection in patients with early-stage breast cancer. Can J Surg (2003) 0.79
Axillary lymph node micrometastases decrease triple-negative early breast cancer survival. Br J Cancer (2016) 0.76
Complications of Axillary Lymph Node Dissection in Treatment of Early Breast Cancer: A Comparison of MRM and BCS. Indian J Surg Oncol (2011) 0.76
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol (2013) 9.68
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med (1998) 5.20
I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther (2009) 5.01
Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res (1996) 4.98
Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys (1997) 4.55
Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst (1998) 4.43
Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol (1999) 4.12
Actin binding proteins: regulation of cytoskeletal microfilaments. Physiol Rev (2003) 4.07
c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med (1994) 3.89
erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst (1998) 3.56
Changes in weight, body composition, and factors influencing energy balance among premenopausal breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol (2001) 3.23
BRCA2 mutations in primary breast and ovarian cancers. Nat Genet (1996) 2.91
Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. J Clin Oncol (1998) 2.55
Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662. Clin Cancer Res (2001) 2.53
A finite-element model of vocal-fold vibration. J Acoust Soc Am (2000) 2.44
Primary care for survivors of breast cancer. N Engl J Med (2000) 2.39
The oxidative DNA lesion 8,5'-(S)-cyclo-2'-deoxyadenosine is repaired by the nucleotide excision repair pathway and blocks gene expression in mammalian cells. J Biol Chem (2000) 2.28
Genetic basis for p53 overexpression in human breast cancer. Proc Natl Acad Sci U S A (1991) 2.27
Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res (1991) 2.20
American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol (1999) 2.03
Detection of frequent allelic loss on proximal chromosome 17q in sporadic breast carcinoma using microsatellite length polymorphisms. Cancer Res (1992) 1.93
Endoscopic release of the carpal tunnel: a randomized prospective multicenter study. J Hand Surg Am (1992) 1.91
Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol (2001) 1.89
Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers. Proc Natl Acad Sci U S A (1992) 1.87
Weight gain in women diagnosed with breast cancer. J Am Diet Assoc (1997) 1.87
Side effects of chemotherapy and combined chemohormonal therapy in women with early-stage breast cancer. J Natl Cancer Inst Monogr (2001) 1.84
Identification of a new subclass of Alu DNA repeats which can function as estrogen receptor-dependent transcriptional enhancers. J Biol Chem (1995) 1.78
Quality of life and preferences for treatment following systemic adjuvant therapy for early-stage breast cancer. J Clin Oncol (1998) 1.66
A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression. Cancer Res (1995) 1.62
Maintenance of p53 alterations throughout breast cancer progression. Cancer Res (1991) 1.58
Nonpalpable breast lesions at biopsy. A detailed analysis of radiographic features. Ann Surg (1988) 1.55
Post-mastectomy radiotherapy following adjuvant chemotherapy and autologous bone marrow transplantation for breast cancer patients with greater than or equal to 10 positive axillary lymph nodes. Cancer and Leukemia Group B. Int J Radiat Oncol Biol Phys (1992) 1.51
Training the radiation oncologist for the twenty-first century. Int J Radiat Oncol Biol Phys (1996) 1.47
BRCA1 expression is induced before DNA synthesis in both normal and tumor-derived breast cells. Cell Growth Differ (1996) 1.45
Use of paravertebral block anesthesia in the surgical management of breast cancer: experience in 156 cases. Ann Surg (1998) 1.43
Prognostic importance of restaging gallium scans following induction chemotherapy for advanced Hodgkin's disease. J Clin Oncol (1994) 1.43
Transforming growth factor beta 1 can induce CIP1/WAF1 expression independent of the p53 pathway in ovarian cancer cells. Cell Growth Differ (1994) 1.42
Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol (2000) 1.41
A million dollar measles outbreak: epidemiology, risk factors, and a selective revaccination strategy. Public Health Rep (1992) 1.41
"One to three" or "four or more"?: selecting patients for postmastectomy radiation therapy. Cancer (1997) 1.41
Elevated plasma transforming growth factor-beta 1 levels in breast cancer patients decrease after surgical removal of the tumor. Ann Surg (1995) 1.40
Prognostic significance of extent of nodal involvement in stage D1 prostate cancer treated with radiotherapy. Urology (1992) 1.40
Assessing the impact of elective regional radiotherapy on survival. Cancer J Sci Am (1999) 1.39
Overexpression of the protein tyrosine phosphatase PTP1B in human breast cancer: association with p185c-erbB-2 protein expression. J Natl Cancer Inst (1994) 1.39
Multivariate analysis of factors predicting local relapse after radical prostatectomy--possible indications for postoperative radiotherapy. Int J Radiat Oncol Biol Phys (1991) 1.38
Reduced rates of metabolism and decreased physical activity in breast cancer patients receiving adjuvant chemotherapy. Am J Clin Nutr (1997) 1.37
Radiotherapy alone for medically inoperable stage I non-small-cell lung cancer: the Duke experience. Int J Radiat Oncol Biol Phys (1998) 1.36
Complications of axillary lymph node dissection for carcinoma of the breast: a report based on a patient survey. Cancer (1998) 1.34
Biochemical and antitumor activity of tiazofurin and its selenium analog (2-beta-D-ribofuranosyl-4-selenazolecarboxamide). Biochem Pharmacol (1985) 1.34
Cell cycle control of BRCA2. Cancer Res (1996) 1.32
Plasma D-dimer levels in operable breast cancer patients correlate with clinical stage and axillary lymph node status. J Clin Oncol (2000) 1.31
M6P/IGF2 receptor: a candidate breast tumor suppressor gene. Oncogene (1996) 1.31
Relation between p53 overexpression and established prognostic factors in breast cancer. Surgery (1991) 1.31
Radiation therapy as initial treatment for early stage cancer of the breast without mastectomy. Cancer (1977) 1.29
Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer. Breast Cancer Res Treat (2011) 1.29
Radiation therapy and hyperthermia improve the oxygenation of human soft tissue sarcomas. Cancer Res (1996) 1.28
Local failure and margin status in early-stage breast carcinoma treated with conservation surgery and radiation therapy. Ann Surg (1993) 1.27
Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy. Ann Oncol (2005) 1.25
Expression of Tie2/Tek in breast tumour vasculature provides a new marker for evaluation of tumour angiogenesis. Br J Cancer (1998) 1.25
BRCA1 expression is not directly responsive to estrogen. Oncogene (1997) 1.24
Male breast cancer: risk factors, biology, diagnosis, treatment, and survivorship. Ann Oncol (2013) 1.24
Quantification of radiation-induced regional lung injury with perfusion imaging. Int J Radiat Oncol Biol Phys (1997) 1.24
NCCN Practice Guidelines for Breast Cancer. Oncology (Williston Park) (2000) 1.22
Why women gain weight with adjuvant chemotherapy for breast cancer. J Clin Oncol (1993) 1.21
Patterns and variability of tumor oxygenation in human soft tissue sarcomas, cervical carcinomas, and lymph node metastases. Int J Radiat Oncol Biol Phys (1995) 1.21
Overexpression of erbB-2 or EGF receptor proteins present in early stage mammary carcinoma is detected simultaneously in matched primary tumors and regional metastases. Oncogene (1989) 1.20
Tolerability of and adherence to combination oral therapy with gefitinib and capecitabine in metastatic breast cancer. Breast Cancer Res Treat (2009) 1.19
Variability of the depth of supraclavicular and axillary lymph nodes in patients with breast cancer: is a posterior axillary boost field necessary? Int J Radiat Oncol Biol Phys (2000) 1.18
The role of three dimensional functional lung imaging in radiation treatment planning: the functional dose-volume histogram. Int J Radiat Oncol Biol Phys (1995) 1.15
Menopausal-type symptoms in young breast cancer survivors. Ann Oncol (2006) 1.15
Expression of p53 in human neuroblastoma- and neuroepithelioma-derived cell lines. Oncogene (1992) 1.13
Inhibition of mitogen-activated protein kinase and phosphatidylinositol 3-kinase activity in MCF-7 cells prevents estrogen-induced mitogenesis. Cell Growth Differ (2000) 1.13
Subgroup analyses. Biometrics (1990) 1.12
p53 overexpression in formalin-fixed, paraffin-embedded tissue detected by immunohistochemistry. J Histochem Cytochem (1992) 1.12
Tumour response interpretation with new tumour response criteria vs the World Health Organisation criteria in patients with bone-only metastatic breast cancer. Br J Cancer (2010) 1.11
Overexpression and mutation of p53 in endometrial carcinoma. Cancer Res (1992) 1.11
Abnormalities of the inactive X chromosome are a common feature of BRCA1 mutant and sporadic basal-like breast cancer. Cold Spring Harb Symp Quant Biol (2005) 1.10
Overexpression of p53 and HER-2/neu proteins as prognostic markers in early stage breast cancer. Ann Surg (1994) 1.08
Cystosarcoma phyllodes. Effective therapy with cisplatin and etoposide chemotherapy. Cancer (1989) 1.06
Improved survival in advanced Hodgkin's disease with the use of combined modality therapy. Int J Radiat Oncol Biol Phys (1990) 1.06
Activated protooncogenes in human lung tumors from smokers. Proc Natl Acad Sci U S A (1991) 1.05
Knowledge, satisfaction, and perceived cancer risk among women diagnosed with ductal carcinoma in situ. J Womens Health Gend Based Med (2001) 1.05
Cardiac perfusion changes in patients treated for breast cancer with radiation therapy and doxorubicin: preliminary results. Int J Radiat Oncol Biol Phys (2001) 1.05
High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: phase I trial in combination with vinblastine. J Natl Cancer Inst (1992) 1.04
Pretreatment oxygenation profiles of human soft tissue sarcomas. Int J Radiat Oncol Biol Phys (1994) 1.04
Attitudes, knowledge, and risk perceptions of women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2. J Clin Oncol (1999) 1.03
The impact of sharing results of a randomized breast cancer clinical trial with study participants. Breast Cancer Res Treat (2008) 1.03
Cancer pain survey: patient-centered issues in control. J Pain Symptom Manage (1998) 1.03
Empirical Eigenfunctions and medial surface dynamics of a human vocal fold. Methods Inf Med (2005) 1.03
Morphological and biochemical properties of a new human breast cancer cell line. Cancer Res (1979) 1.02
A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma: cancer and leukemia group B study 9181. Cancer (2000) 1.01
Relationship between p21 expression and mutation of the p53 tumor suppressor gene in normal and malignant ovarian epithelial cells. Clin Cancer Res (1996) 1.01
Stopping a clinical trial early: frequentist and Bayesian approaches applied to a CALGB trial in non-small-cell lung cancer. Stat Med (1994) 1.00
Assessing the cost-effectiveness of postmastectomy radiation therapy. Int J Radiat Oncol Biol Phys (1999) 0.99